# A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Source: https://onco.cc/trials/nct02050321/  
OnCo record `nct02050321` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acitretin and Vemurafenib in Melanoma, run by University of Arizona, recorded as terminated on the registry.

## Summary

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma is a phase 2 interventional study registered as NCT02050321 by University of Arizona, with 2 participants recorded, started 2013-12 and due to reach its primary completion in 2014-12. Interventions recorded: Acitretin, Vemurafenib. Conditions recorded: Malignant Melanoma.

Linked to the drug Acitretin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02050321
- Phase: 2
- Setting: A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
- Sponsor: University of Arizona
- Enrolled: 2

## Sources

- ClinicalTrials.gov NCT02050321: https://clinicaltrials.gov/study/NCT02050321

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Acitretin](https://onco.cc/drugs/acitretin/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)

---
JSON: https://onco.cc/api/v1/entities/nct02050321.json